Meyer D, Anderson D E, Gardner M B, Torres J V
Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, 95616, USA.
AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):751-60. doi: 10.1089/aid.1998.14.751.
Using synthetic peptides, we developed an approach to account for protein epitope variability. We have prepared, in a single synthesis, a cocktail of peptides we have designated a hypervariable epitope construct (HEC), which collectively represents much of the in vivo variability seen in an epitope. Eight HECs representing the in vivo variability seen throughout the envelope glycoprotein of the simian immunodeficiency virus (SIV) were designed and synthesized. The constructs were collectively conjugated to KLH (HEC-KLH) or recombinant gp130 (HEC-rgp130) and used to immunize rabbits and rhesus macaques, respectively. Using sera collected from rabbits immunized with HEC-KLH, we demonstrated that individual components of the immunogen were recognized as antigen in ELISAs, and that the induced antibodies cross-reacted with several strains of SIV as well as with a strain of HIV-2. Following immunization of macaques with HEC-rgp130 antiviral antibodies were induced. These antibodies were still present 9.5 months after the last boost and were also capable of recognizing several different strains of SIV, including SIVmac239, SIVmac251, and SIVsmH3, as well as a strain of HIV-2 (HIV-2ROD). In addition, the antibodies were also capable of neutralizing SIV viral infectivity in vitro. Peripheral blood lymphocytes (PBLs) from immunized macaques proliferated in response to whole proteins and virus. Finally, sera from monkeys immunized with SIV, rgp130, and HIV-2 as well as sera from HIV-2-positive humans recognized HECs in ELISAs, demonstrating the relevance of these epitopes in vivo. This approach can be used as an effective method for generating a strong, broadly cross-reactive humoral response against HIV and can serve as an important component of combination vaccines against HIV and AIDS.
我们利用合成肽开发了一种方法来解释蛋白质表位的变异性。我们在一次合成中制备了一种肽混合物,我们将其命名为高变表位构建体(HEC),它共同代表了表位在体内所见的大部分变异性。设计并合成了八个代表猿猴免疫缺陷病毒(SIV)包膜糖蛋白在体内变异性的HEC。这些构建体分别与钥孔血蓝蛋白(HEC-KLH)或重组gp130(HEC-rgp130)偶联,并分别用于免疫兔子和恒河猴。利用从用HEC-KLH免疫的兔子收集的血清,我们证明免疫原的各个组分在酶联免疫吸附测定(ELISA)中被识别为抗原,并且诱导的抗体与几种SIV毒株以及一种HIV-2毒株发生交叉反应。在用HEC-rgp130免疫恒河猴后诱导出抗病毒抗体。这些抗体在最后一次加强免疫后9.5个月仍然存在,并且也能够识别几种不同的SIV毒株,包括SIVmac239、SIVmac251和SIVsmH3,以及一种HIV-2毒株(HIV-2ROD)。此外,这些抗体在体外也能够中和SIV病毒感染性。免疫的恒河猴的外周血淋巴细胞(PBL)对全蛋白和病毒有增殖反应。最后,用SIV、rgp130和HIV-2免疫的猴子的血清以及HIV-2阳性人类的血清在ELISA中识别HEC,证明这些表位在体内的相关性。这种方法可以用作产生针对HIV的强烈、广泛交叉反应性体液反应的有效方法,并且可以作为抗HIV和艾滋病联合疫苗的重要组成部分。